Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial

BACKGROUND: The long-term consequences of human umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment for COVID-19 patients are yet to be reported. This study assessed the 1-year outcomes in patients with severe COVID-19, who were recruited in our previous UC-MSC clinical trial. METHODS: I...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Lei, Yuan, Xin, Yao, Weiqi, Wang, Siyu, Zhang, Chao, Zhang, Bo, Song, Jinwen, Huang, Lei, Xu, Zhe, Fu, Jun-Liang, Li, Yuanyuan, Xu, Ruonan, Li, Tian-Tian, Dong, Jinghui, Cai, Jianming, Li, Genshi, Xie, Yunbo, Shi, Ming, Li, Yonggang, Zhang, Yu, Xie, Wei-Fen, Wang, Fu-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709782/
https://www.ncbi.nlm.nih.gov/pubmed/34963099
http://dx.doi.org/10.1016/j.ebiom.2021.103789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709782/
https://www.ncbi.nlm.nih.gov/pubmed/34963099
http://dx.doi.org/10.1016/j.ebiom.2021.103789

Ejemplares similares